• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

T Regulatory Cell Therapies

Background

Neuroinflammation was discovered many years ago to be a key contributor to the degeneration of motor neurons in ALS. Cells called microglia that surround motor neurons and provide immune protection to a healthy central nervous system, lose some of their normal function while becoming abnormally activated, secreting substances that likely increase motor neuron damage. Other cells, called T cells, travel in the bloodstream and are capable of exiting into the area near motor neurons, where they can play a neuroinflammatory role. Through studying the aspects of T cells in ALS more closely it was discovered that certain types of T cells, called regulatory T cells (Tregs), can also be protective and naturally reduce these neuroinflammatory effects. Furthermore, the level of effective Tregs is lower in people with ALS and the amount of Tregs is correlated with rate of disease progression (ie. more in slower progressors, less in fast). As a result, treatment strategies attempting to increase the body’s production of Tregs or to provide more of them have been advanced to clinical trial in recent years. A number of trials are examining regulatory T cells as a primary means of treating ALS or as a contributor to a treatment strategy.

These include:

  1. Dr. Stanley Appel’s regulatory T cell transplants and Coya Therapeutics –Dr. Appel is the initial champion for the potential in targeting Tregs as a treatment for ALS, including founding research over a decade ago that demonstrated their protective effects in mouse models. In this treatment regimen, Tregs are removed from blood (a process called leukapheresis), multiplied in number outside the body (in a lab), and returned intravenously (IV) along with a subcutaneous low dose of a substance called interleukin-2 (IL-2), which helps stabilize the Tregs.
    • Coya 101
      • An initial clinical trial of Treg treatment in three individuals demonstrated very intriguing results (1) that warranted a phase 2 trial in 7 participants. It is important to note that the first trial was extremely small so interpretation of effect cannot be made at this point. The phase 2 trial looked at a combined treatment of Tregs and IL-2 and was a double-blind, placebo-controlled trial to primarily assess safety and effect on immune and inflammatory ALS effects. There was a six month open label extension for all participants after six months of study during which they found that Treg/IL-2 was safe and well tolerated and increased the function of Tregs in people with ALS but not the numbers (results published here). A larger trial is needed to assess whether Treg/IL-2 treatment can slow disease progression.
    • Coya 302
      • A small trial of a combination of IL-2 and CTLA4-Ig (a protein designed to decrease the activity of immune cells that promote inflammation) was
        conducted in 4 participants. The trial involved treatment with Coya 302 for a total of 48 weeks. It was found to be safe and well tolerated with no
        serious side effects. Increased Treg activity and a decrease of other markers of inflammation were found during treatment, but these effects wore off once treatment stopped. The results also suggested a transient and minimal change in ALSFRS-R score, as a measure of disease progression, throughout the study. Due to the small size of the trial, a larger placebo-controlled phase 2 trial is needed to continue testing whether this could be beneficial for ALS.
  2. RAPA-501 Therapy – Rapa Therapeutics conducted an open label phase 1 trial of RAPA-501 T cells where T cells were removed from blood, treated outside the body (in a lab) with substances to both increaseTreg activity and reduce other inflammatory cell activity, followed by IV reintroduction of the cells to the participant with or without a regimen (called PC regimen) designed to assist in the Rapa T cell effectiveness. This trial aimed to establish safety and an effective dose to use. This phase 1 trial has led to a further phase 2/3 open label trial of RAPA-501 where all participants will receive treatment with RAPA 501. This is currently underway and assessing the safety of the highest dose and effectiveness on T cells function.
  3. Rapamycin (RAP-ALS) – An academic phase 2 trial at eight sites in Italy studied the effects of oral rapamycin on ALS over 18 weeks of treatment, followed by 36 months of follow up. Rapamycin is thought to both increase Treg cell number as well as help autophagic degradation of various aggregate-prone
    proteins. The trial in 63 people analysed levels of biomarkers and other key metrics of how the treatment acts in the body. The primary goal of the trial was to measure Treg levels. The trial found that some people on the treatment had an increase in numbers of Tregs compared to those on placebo but the difference was not statistically significant. It was also found that it may help to decrease inflammation but further studies are needed to fully assess the effects on Tregs and better understand how rapamycin works in the body (published here).
  4. MIROCALS Trial – A joint academic effort between UK and French researchers, the Modifying Immune Response and OutComes in ALS (MIROCALS) trial examined low dose IL-2 alone over 18 months to determine if it is sufficient to enhance a person’s own Tregs. This was a large trial that recruited 220 people across 17 clinics and participants were studied over 18 months for an effect on disease progression and survival. Although the results initially announced at the International Symposium in December 2022 were encouraging, results from the trial are not yet published. IL-2 was found to be safe and well tolerated. Side effects were minimal across both treatment and placebo. The primary endpoint (measure) for the trial was survival. The ‘raw analysis’ of the results showed only a modest and non-significant decrease in the risk of death in those who received IL-2 compared to the placebo at the end of the trial. However, when the analysis included a statistical adjustment, using neurofilament heavy chain (pNfH) levels as a way of predicting progression rate, the researchers found a statistically significant decrease in the risk of death for a subgroup of people in the trial with a less aggressive form of the disease. ALS symptoms did continue to progress in both the placebo and IL-2 group, which resulted in people still dying in both groups from their ALS. The results are preliminary and encouraging but further analysis of samples and data are ongoing that will answer crucial questions about the outcomes of the trial. Notably, Treg numbers were robustly increased in those receiving IL-2 vs. placebo, both in this study and a prior, preliminary study called IMODALS.
  5. Nebulized RNS60 –Revalesio Corporation tested an inhaled experimental drug  that contains oxygenated nanobubbles called RNS60, and has demonstrated  anti-inflammatory and neuroprotective effects in preclinical ALS models. One of  the effects demonstrated in mice was an increase in Tregs. A small investigator initiated, open label, pilot trial has previously established safety and tolerability  (2). RNS60 was tested in a phase 2 clinical trial of 147 participants and markers  of inflammation were measured. The trial found no difference in these markers  between those on RNS60 and those on placebo, suggesting that it did not have  an effect on the immune system or Tregs. However, it was found to have some  benefit in slowing decline in respiratory and bulbar functions (e.g. swallowing  and talking) (published here). Further trials of RNS60 are needed to continue to  investigate these effects.

Recommendation

The SAC recommends that caution be taken in interpreting the effectiveness of the different approaches targeting regulatory T cells as a treatment for ALS. While promising preclinical science and clinical trial data exists in small study samples, it is too early to know if any of these strategies are truly effective. Each of these are exciting in their possibilities for treating ALS and the SAC looks forward to learning more from rigorous studies in the time ahead.

References

1. Expanded autologous regulatory T-lymphocyte infusions in ALS | Neurology Neuroimmunology & Neuroinflammation
2. A Pilot Trial of RNS60 in Amyotrophic Lateral Sclerosis – PMC (nih.gov)

International Alliance of ALS/MND Associations
March 2024 


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • ILB – Tikomed
  • Kadimastem – AstroRx
  • Methylcobalamin
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Neuronata-R/Lenzumestrocel
  • NeuroSense – PrimeC
  • Neuvivo – NP001
  • T Regulatory Cell Therapies
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials

  • Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

    Jean Waters, Diagnosed 2004, MND Association of England, Wales and N Ireland

  • Richard Clark, MND New Zealand,  Diagnosed 2011

    Richard Clark, MND New Zealand, Diagnosed 2011

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Dad

    Dad

  • Claudia Cominetti, Associazione conSLAncio Onlus,  Italy

    Claudia Cominetti, Associazione conSLAncio Onlus, Italy

  • March of Faces Photo Submission_ALEX_ELA ARGENTINA

    March of Faces Photo Submission_ALEX_ELA ARGENTINA

  • Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

  • Aida Trzmiel de Guterman, Asociacion ELA Argentina, Diagnosed 2007, Argentina

    Aida Trzmiel de Guterman, Asociacion ELA Argentina, Diagnosed 2007, Argentina

  • Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

    Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

  • Denis Blais, Diagnosed 2015 , ALS Canada

    Denis Blais, Diagnosed 2015 , ALS Canada

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

    Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

  • John Dinon, MND Australia

    John Dinon, MND Australia

  • Dr Shelly Hoover

    Dr Shelly Hoover

  • Eddy LeFrançois, Diagnosed 1992,  ALS Canada

    Eddy LeFrançois, Diagnosed 1992, ALS Canada

  • Marcel R. Wernard, Diagnosed 2016,  ALS Patients Connected,  The Netherlands

    Marcel R. Wernard, Diagnosed 2016, ALS Patients Connected, The Netherlands

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Zelina Brito, Diagnosed 2018, Brazil

    Zelina Brito, Diagnosed 2018, Brazil

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Orlando Ruiz, Diagnosed 2001,  ACELA, Colombia

    Orlando Ruiz, Diagnosed 2001, ACELA, Colombia

  • Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

    Elkin Ramiro Gaviria Muñoz, Diagnosed December 2018

  • Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

    Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Monica Soriano, Diagnosed 2011 ,  Asociación ELA , Argentina

    Monica Soriano, Diagnosed 2011 , Asociación ELA , Argentina

  • Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

    Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Jason Goodman, Les Turner ALS Foundation, USA

    Jason Goodman, Les Turner ALS Foundation, USA

  • Ali Var, Turkey

    Ali Var, Turkey

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Yessenia Hernandez Mendoza, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Len Johnrose,  MND Association,  Diagnosed 2017,  England

    Len Johnrose, MND Association, Diagnosed 2017, England

  • Rosie Riley, Les Turner ALS Foundation, USA

    Rosie Riley, Les Turner ALS Foundation, USA

  • Mauril Bélanger, Diagnosed 2015 , ALS Canada

    Mauril Bélanger, Diagnosed 2015 , ALS Canada

  • Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

    Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • Cassio Fernando da Silva, Diagnosed 2013 , ABrELA, Brazil

    Cassio Fernando da Silva, Diagnosed 2013 , ABrELA, Brazil

  • March of Faces Photo Submission_OLGA_ELA ARGENTINA

    March of Faces Photo Submission_OLGA_ELA ARGENTINA

  • Wilfried Leusing

    Wilfried Leusing

  • Lombana, Spain

    Lombana, Spain

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Inta Grubb, Diagnosed 2014,  MND Australia

    Inta Grubb, Diagnosed 2014, MND Australia

  • Debbie Craghill, USA

    Debbie Craghill, USA

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

    Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

  • Philip Brindle,  MND Association,  Diagnosed 2015,  England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • Frank "Papa" Taylor

    Frank “Papa” Taylor

  • Fabio Carvalho

    Fabio Carvalho

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

    Charlie “Hark” Dourney, Diagnosed 2007 , Hark ALS, USA

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login